Receptor tyrosine kinases: from biology to pathology

References

• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211–225.
   PubMed Web of Science ®Google Scholar
• Patthy L. Modular exchange principles in proteins. Curr Opin Struct Biol 1991, 1, 351–361.
   Google Scholar
• Patthy L. Introns and exons. Curr Opin Struct Biol 1994, 4, 383–392.
   Google Scholar
• Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993, 62, 453–481.
   PubMed Web of Science ®Google Scholar
• Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80, 213–223.
   PubMed Web of Science ®Google Scholar
• Drescher U. Eph family functions from an evolutionary perspective. Curr Opin Genet Dev 2002, 12, 397–402.
   PubMedGoogle Scholar
• Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994, 368, 643–648.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134.
   PubMed Web of Science ®Google Scholar
• Bae JH, Schlessinger J. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol Cells 2010, 29, 443–448.
   PubMedGoogle Scholar
• Brognard J, Hunter T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev 2011, 21, 4–11.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411, 355–365.
   PubMed Web of Science ®Google Scholar
• Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006, 45, 6241–6251.
   PubMed Web of Science ®Google Scholar
• Sigalov AB, editor. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease. Springer-Verlag, New York, 2008.
   Google Scholar
• Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromes when good receptors turn bad. Trends Genet 2000, 16, 265–271.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19, 3159–3167.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010, 5, 1734–1740.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23, 2556–2568.
   PubMed Web of Science ®Google Scholar
• Yun YR, Won JE, Jeon E, Lee S, Kang W, Jo H, Jang JH, Shin US, Kim HW. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010, 2010, 218142.
   PubMedGoogle Scholar
• Wilikie AO. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 2005, 16, 187–203.
   Google Scholar
• Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006, 24, 3747–3755.
   PubMedGoogle Scholar
• Raile K, Klammt J, Schneider A, Keller A, Laue S, Smith R, Pfäffle R, Kratzsch J, Keller E, Kiess W. Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor i receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1R. J Clin Endocrinol Metab 2006, 91, 2264–2271.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298, 1912–1934.
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10, 165–180.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26, 5352–5359.
   PubMed Web of Science ®Google Scholar
• Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990, 87, 1377–1380.
   PubMed Web of Science ®Google Scholar
• Springall F, O’Mara S, Shounan Y, Todd A, Ford D, Iland H. c-fms point mutations in acute myeloid leukemia: fact or fiction? Leukemia 1993, 7, 978–985.
   Google Scholar
• Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 2009, 10, 1839–1851.
   PubMed Web of Science ®Google Scholar
• Mäkinen T, Norrmén C, Petrova TV. Molecular mechanisms of lymphatic vascular development. Cell Mol Life Sci 2007, 64, 1915–1929.
   PubMedGoogle Scholar
• Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000, 25, 153–159.
   PubMed Web of Science ®Google Scholar
• Lehmann K, Seemann P, Silan F, Goecke TO, Irgang S, Kjaer KW, Kjaergaard S, Mahoney MJ, Morlot S, Reissner C, Kerr B, Wilkie AO, Mundlos S. A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN. Am J Hum Genet 2007, 81, 388–396.
   Google Scholar
• Katoh M, Katoh M. Comparative integromics on non-canonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells. Int J Mol Med 2007, 20, 405–409.
   Google Scholar
• Kaplan DR, Stephens RM. Neurotrophin signal transduction by the Trk receptor. J Neurobiol 1994, 25, 1404–1417.
   PubMedGoogle Scholar
• Sarasola Rodriguez JA, Garrote E, Aristegui J, Garcia-Barcina MJE. A short in-frame deletion in NRTK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensivity to pain with anhidrosis. BMC Med Genet 2011, 12, 86.
   Google Scholar
• Guo H, Barrett TM, Zhong Z, Fernández JA, Griffin JH, Freeman RS, Zlokovic BV. Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener 2011, 6, 13.
   Google Scholar
• Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, Kay NE. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011, 117, 1928–1937.
   PubMed Web of Science ®Google Scholar
• Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 2011, 71, 1792–1804.
   PubMed Web of Science ®Google Scholar
• Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994, 5, 647–657.
   PubMedGoogle Scholar
• Chan MC, Mather JP, McCray G, Lee WM. Identification and regulation of receptor tyrosine kinases Rse and Mer and their ligand Gas6 in testicular somatic cells. J Androl 2000, 21, 291–302.
   PubMedGoogle Scholar
• Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, Oyesiku NM. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2001, 86, 3097–3107.
   PubMed Web of Science ®Google Scholar
• Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102, 2951–2959.
   Google Scholar
• Funakoshi H, Yonemasu T, Nakano T, Matumoto K, Nakamura T. Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons. J Neurosci Res 2002, 68, 150–160.
   PubMed Web of Science ®Google Scholar
• Saharinen P, Bry M, Alitalo K. How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 2010, 17, 198–205.
   Google Scholar
• Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996, 87, 1181–1190.
   PubMed Web of Science ®Google Scholar
• Sagara Y, Miyata Y, Nomata K, Abe K, Eguchi J, Hayashi T, Sakai H, Kanda S, Kanetake H. TFE3-renal carcinoma in an adult patient: a case with strong expression of phosphorylated hepatocyte growth factor (HGFR)/Met. Pathol Res Pract 2009, 205, 57–61.
   PubMedGoogle Scholar
• Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res 2011, 71, 1945–1955.
   Google Scholar
• Qi XP, Ma JM, Du ZF, Ying RB, Fei J, Jin HY, Han JS, Wang JQ, Chen XL, Chen CY, Liu WT, Lu JJ, Zhang JG, Zhang XN. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. PLoS ONE 2011, 6, e20353.
   Google Scholar
• Martínez I, Mantilla A, Medrano ME, Hernández R, Hernández DM, Lazos M, Santiago H, González B, Hidalgo A, Salcedo M. High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas. Endocr Pathol 2001, 12, 113–123.
   PubMedGoogle Scholar
• Chevessier F, Faraut B, Ravel-Chapuis A, Richard P, Gaudon K, Bauché S, Prioleau C, Herbst R, Goillot E, Ioos C, Azulay JP, Attarian S, Leroy JP, Fournier E, Legay C, Schaeffer L, Koenig J, Fardeau M, Eymard B, Pouget J, Hantaï D. Towards the molecular elucidation of congenital myasthenic syndromes: identification of mutations in MuSK. Acta Myol 2005, 24, 55–59.
   Google Scholar